Irini Flouri

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

Irini Flouri, Theodora E. Markatseli, Paraskevi V. Voulgari et al. · Seminars in Arthritis and Rheumatism · 2013 · 92 citations

Rheumatoid Disorder, Rheumatology, Medicine +10

Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence

Irini Flouri, Theodora E. Markatseli, Kyriaki Boki et al. · The Journal of Rheumatology · 2018 · 56 citations · Full text

Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study.

Ioannis Papalopoulos, Antonis Fanouriakis, Nikolaos Kougkas et al. · PubMed · 2018 · 33 citations

High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.

Κonstantinos Thomas, Irini Flouri, Argiro Repa et al. · PubMed · 2018 · 26 citations

Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression

Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis et al. · Annals of the Rheumatic Diseases · 2024 · 25 citations · Full text